2020 China Blood Disease Conference, President Lu Peihua talks about the hot topic of blood disease.

Introduction: August 14-15, 2020, China Hematology Congress and the 14th Annual Meeting of Hematologists of the Chinese Physicians Association, held by online and offline.
, August 24, 2020 /AGENCY/-- August 14-15, 2020, The China Hematology Congress and the 14th Annual Meeting of Hematologists of the Chinese Physicians Association were held online and offline. The
conference, on the basis of adhering to the characteristics of previous sessions, added innovative content, invited a number of domestic academicians, well-known scholars on scientific research methods, translational medicine, hematology hot areas and other issues to give a keynote speech, and set up a "debate and contention topic" venue, on the current major scientific progress in hematology, clinical research and other hot and difficult issues have been actively discussed and in-depth discussion.
Huang Xiaojun, Director of the Institute of Hematology, Peking University, Professor Wu Depei of the First Hospital affiliated with Suzhou University, served as President of the General Assembly, and Professor Kaiyan Liu, Deputy Director of the Institute of Hematology of Peking University, served as Executive Chairman of the General Assembly.
Lu Peihua, Executive Director of Medical Services at Lu Daopei Hospital in China, was invited to attend the conference and bring about a wonderful debate.
In the academic hot debate session, Professor Lu Peihua and Professor Huanghe, Dean of the First Hospital affiliated with Zhejiang University, had a wonderful debate on "the need for bridged secondary transplantation after the treatment of CAR-T in patients with post-transplant relapse", and the two experts expounded their own views from both positive and positive aspects, and the whole debate was clear, well-evidenced, and the spark of communication inspired everyone's thinking.
car-T immunocellular therapy from the first generation to the second generation, single-target to dual-target, mouse source and human origin, to B-cell blood tumor treatment opened a new chapter.
From a typical case of B-ALL that relapses after transplantation, Professor Lu Peihua focuses on the study of the recurrence of B-ALL at Lu Daopei Hospital after transplantation for separate CAR-T treatment and the secondary transplantation of CAR-T rear bridal.
two studies have shown that for patients with relapsed B-ALL after transplantation, most of them can still achieve MRD-negative CR through CAR-T cell infusion and are safe.
this part of the patient can obtain MRD-negative CR through CAR-T cell therapy, may consider a second transplant, secondary transplant safety is good, can benefit.
but the second transplant needs to meet certain conditions: CAR-T can reach MRD-negative CR, CAR-T after in activity GVHD, there is a suitable provider, the whole body condition allows.
The Team of Professor Huanghe lists the current effectiveness of CART treatment and the fact that after re-treatment after transplantation, it is still in a fully inset state, where patients can sustain long-term remission and need to take full account of the risk of a second transplant.
Also participating in the discussion on the spot is Professor Tang Xiaowen of the First Hospital affiliated with Suzhou University, Professor Han Mingzhe of Tianjin Institute of Hematology, Professor Yang Jianmin of Changhai Hospital of the Second Military Medical University, and Professor Xu Kailin of Xuzhou Medical University. Professor Liu Daihong of PLA General Hospital 301, we discussed the need for a second transplant to re-layer the patients and the current status and prospects of CART preparation and infusion, and so on, and talked freely and exchanged their experiences.
treatment is controversial, academic issues need to be debated, the truth is more clear, in the contention of consensus - this is the 2020 China Blood Disease Congress set "debate and contention topic" meaning.
is more conducive to the promotion and development of China's hematology discipline, benefit more patients.
constantly, with the development of medical science, CAR-T as a new treatment to those who are difficult to treat / relapse / drug-resistant blood disease patients bring new hope.
patients with complex or drug-resistant conditions are treated with CAR-T, tumor cells are relieved, preparing for bridgied transplantation.
Hospital in 2015 began conducting clinical trials in this area, is one of the first in the country to carry out this research single center.
Through many years of exploration, summary, improvement and improvement, with the support of a number of CAR-T preparation companies, our hospital in CAR-T cell therapy difficult /recurring B-cell acute lymphoblastic leukemia, lymphoma, myeloma and other hematological patients have accumulated a lot of experience.
2020 China Hematology Conference and the 14th Annual Meeting of Chinese Physicians Association Hematologists is a national blood peer online and offline interaction of the event, the Chinese Physicians Association hematologists gathered in the beautiful Suzhou, a total of the event to talk about the future, will continue to improve the professional quality of Chinese hematologists, clinical capacity, and constantly promote the growth of young talent.
Chinese "blood man" to explore the discipline will never stop!